FDA refuses to review Moderna flu vaccine
Ella Jeffries / beckershospitalreview - Moderna has received a refusal-to-file letter from the FDA’s Center for Biologics Evaluation and Research for its biologics license application for mRNA-1010, its investigational seasonal influenza vaccine. The letter, signed by Vinayak Prasad, MD, chief …
AI Summary: Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making.
Related Stories
FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 3 months
FDA launches individualized therapy framework for ultra-rare diseases / 4 months
FDA makes one pivotal trial the default for drug approvals / 4 months
FDA rejects Atara cell therapy for Epstein–Barr virus complications / 5 months
Boehringer gains fast approval for first‑line lung cancer drug via voucher program / 4 months
FDA clears first new sunscreen ingredient in two decades / 28 days
FDA commissioner Marty Makary resigns amid mounting scrutiny / 1 month
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Healthcare Finance, Drug Pricing, FDA, Medicare Advantage (not listed) and look for the RSS link.
StackHealth Time Machine